Biomarck is pleased to announce its inclusion on COVID-19 Drug Treatment Trackers: Milken Institute COVID-19 Treatment and Vaccine Tracker | Artis Ventures

BIO 11006: A New Well tolerated Therapy

BIO-11006 is the 10 amino acid N-terminal of MARCKS Protein

  • Blocks phosphorylation of MARCKS Protein
  • Ac-Gly-Ala-Gin-Phe-Ser-Lys-Thr-Ala-Ala-Lys-OH
  • Myristoylis replaced with acetate to increase solubility
bio-11006-1

In the hyperstimulated state of inflammatory cells in ARDS, phosphorylation of MARCKS is dramatically increased, allowing for reorganization of the actin cytoskeleton and release and activation of PIP2 enhancing cell migration

bio-11006-2

MARCKS protein plays a major role in regulation of inflammation and cell motility;
BIO-11006 Dephosphorylates MARCKS, inhibiting migration of inflammatory cells

MARCKS regulates the orientation of the actin cytoskeleton within cells. Phosphorylated MARCKS orients the actin filaments to facilitate contraction and cell movement. When BIO 11006 d ephosphorylates MARCKS, it alters the cytoskeletal arrangement. This is demonstrated below: Here, very motile cells with highly phosphorylated MARCKS (human lung cancer cells) are exposed to BIO 11006.. BIO 11006 clearly disrupts MARCKS cytoskeleton associations; in these pictures , the contractile protein Actin , critical for cell movement , is stained green . BIO 11006 Causes a Change in Morphology of these Cells from Rectangular with Actin on Periphery (Motile Cells) to Flattened, Structural Cells with Actin Stress Fibers and Focal Adhesions
Apparent. (Note: The below cells are at the same magnification

UNTREATED CONTROL CELLS

bio-11006-4

TREATED WITH BIO 11006 (100 ? M) 4 HRS

bio-11006-5